Anavex Life Sciences (AVXL) Return on Capital Employed (2017 - 2022)
Anavex Life Sciences (AVXL) posted Return on Capital Employed of 61.67% for Q2 2022, down 69.12% sequentially from 199.69% in Q1 2022.
Anavex Life Sciences (AVXL) Return on Capital Employed (2017 - 2022) Analysis & Trends
Anavex Life Sciences has reported Return on Capital Employed for 6 years, with the latest figure at 61.67% in Q2 2022.
- Quarterly Return on Capital Employed changed N/A year-over-year to 61.67% in Q2 2022, while the trailing twelve-month figure through Jun 2022 was 61.67% (changed N/A YoY) and the FY2021 annual result came in at 48.12%, up 8925.0% from the prior year.
- Return on Capital Employed slipped to 61.67% in Q2 2022 per AVXL's latest filing, from 199.69% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 295.19% in Q3 2021 and troughed at 102.44% in Q1 2019.
- A 5-year average of 39.64% and a median of 38.74% in 2018 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2019 and 2021: Return on Capital Employed plunged 5913 bps in 2019, then soared 28285 bps in 2021.
- Over 5 years, Return on Capital Employed stood at 78.66% in 2018, then jumped by 40 bps to 46.85% in 2019, then surged by 285 bps to 86.45% in 2020, then jumped by 232 bps to 286.93% in 2021, then sank by 79 bps to 61.67% in 2022.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 61.67%, 199.69%, and 286.93% for Q2 2022, Q1 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 61.67% |
| Mar 31, 2022 | 199.69% |
| Dec 31, 2021 | 286.93% |
| Sep 30, 2021 | 295.19% |
| Mar 31, 2021 | 243.24% |
| Dec 31, 2020 | 86.45% |
| Sep 30, 2020 | 51.42% |
| Jun 30, 2020 | 11.26% |
| Mar 31, 2020 | -39.61% |
| Dec 31, 2019 | -46.85% |
| Sep 30, 2019 | -70.44% |
| Jun 30, 2019 | -87.61% |
| Mar 31, 2019 | -102.44% |
| Dec 31, 2018 | -78.66% |
| Sep 30, 2018 | -54.39% |
| Jun 30, 2018 | -38.74% |
| Mar 31, 2018 | -43.31% |
| Dec 31, 2017 | -32.44% |
| Sep 30, 2017 | -31.12% |